BlackRock Inc. increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1.0% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 30,875,633 shares of the biotechnology company’s stock after acquiring an additional 290,882 shares during the quarter. BlackRock Inc. owned about 0.10% of Exelixis worth $734,839,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Blume Capital Management Inc. acquired a new stake in Exelixis during the 4th quarter worth approximately $152,000. Oregon Public Employees Retirement Fund raised its holdings in Exelixis by 1,978.9% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,319,939 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 2,208,347 shares during the last quarter. Vanguard Group Inc raised its holdings in Exelixis by 3.2% during the 3rd quarter. Vanguard Group Inc now owns 26,527,089 shares of the biotechnology company’s stock worth $470,060,000 after purchasing an additional 834,478 shares during the last quarter. AlphaCrest Capital Management LLC bought a new position in Exelixis during the 4th quarter worth approximately $346,000. Finally, Prudential Financial Inc. raised its holdings in Exelixis by 451.9% during the 4th quarter. Prudential Financial Inc. now owns 1,598,167 shares of the biotechnology company’s stock worth $31,435,000 after purchasing an additional 1,308,617 shares during the last quarter. Institutional investors and hedge funds own 78.27% of the company’s stock.

Several research firms have issued reports on EXEL. ValuEngine upgraded shares of Exelixis from a “sell” rating to a “hold” rating in a report on Friday, May 24th. BidaskClub upgraded shares of Exelixis from a “sell” rating to a “hold” rating in a report on Thursday, May 23rd. Morgan Stanley set a $27.00 price target on shares of Exelixis and gave the stock a “hold” rating in a report on Thursday, May 2nd. Cowen restated a “buy” rating and set a $29.00 price target on shares of Exelixis in a report on Tuesday, April 23rd. Finally, Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $26.00 price target for the company in a report on Tuesday, April 16th. Six research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Exelixis presently has a consensus rating of “Buy” and a consensus price target of $28.88.

Exelixis stock opened at $19.60 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.56 and a quick ratio of 7.48. Exelixis, Inc. has a 52-week low of $13.42 and a 52-week high of $25.31. The company has a market cap of $5.91 billion, a price-to-earnings ratio of 15.07, a PEG ratio of 0.46 and a beta of 1.98.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.24 earnings per share for the quarter, meeting the consensus estimate of $0.24. The company had revenue of $215.49 million during the quarter, compared to analyst estimates of $206.06 million. Exelixis had a net margin of 75.97% and a return on equity of 37.21%. Exelixis’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.40 EPS. Analysts forecast that Exelixis, Inc. will post 0.92 earnings per share for the current year.

In other news, CMO Gisela Schwab sold 100,000 shares of Exelixis stock in a transaction on Monday, March 25th. The shares were sold at an average price of $23.14, for a total value of $2,314,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick J. Haley sold 2,000 shares of Exelixis stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. The disclosure for this sale can be found here. Insiders sold a total of 562,889 shares of company stock valued at $12,735,664 in the last quarter. 4.50% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “BlackRock Inc. Acquires 290,882 Shares of Exelixis, Inc. (EXEL)” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2019/06/04/blackrock-inc-acquires-290882-shares-of-exelixis-inc-exel.html.

Exelixis Company Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: What is a Stop Order?

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.